China's Pharma Industry Is Booming — Here's Why | China Decode

China’s emergence as a global biotech superpower is reshaping the pharmaceutical landscape, driven by decades of strategic industrial policy, talent recruitment, and regulatory alignment. The country’s biotech ecosystem now produces high-quality, cost-effective drug assets, with out-licensing deals to multinational companies accelerating significantly. Physician and author Ruby Wang notes that China’s rapid innovation cycle and integration of AI in drug discovery are forcing global reliance, even as geopolitical tensions persist. While the U.S. maintains a competitive stance, China’s dominance in rare earth supplies and its growing capacity for clinical trials underscore a shifting power dynamic. By 2030, China could account for 30% of global pharmaceutical innovation, positioning its domestic biotech sector as a critical component of the future global health infrastructure, increasingly independent of traditional Western-led models.